摘要
目的探讨宫颈癌患者肿瘤标志物检测的临床意义。方法选择1 157例宫颈肿瘤患者为宫颈肿瘤疾病组,其中宫颈良性疾病患者841例、宫颈癌患者316例,选择1 204例健康女性体检者为对照组,采用化学发光分析仪测血清中甲胎蛋白(AFP)、癌胚抗原(CEA)、糖类抗原125(CA125)、糖类抗原199(CA19-9)、糖类抗原153(CA15-3)、铁蛋白(FER)、鳞癌相关抗原(SCC)。结果与对照组、宫颈良性疾病组比较,宫颈癌组CEA、CA125、CA19-9、CA15-3、FER、SCC均上升,与对照组比较,宫颈良性疾病组CA125、CA15-3、FER、SCC略微升高;SCC变化与肿瘤临床分期、肿瘤病理分级、淋巴结转移相关;在宫颈良性疾病组、宫颈癌组患者中,多项肿瘤标志物联合检测阳性率高于各单项指标检测阳性率,宫颈癌组高于宫颈良性疾病组,差异均有统计学意义(P<0.05)。结论多项肿瘤标志物联合检测可大大提高对宫颈癌患者鉴别诊断的准确性。
Objective To research the clinical significance of tumor markers detection in patients with cervix cancer. Methods 1 157 patients with cervix tumor served as desease group,of which 841 cases were benign group and the rest 316 cases were the cervix cancer group. Meanwhile,1 204 female healthy people served as control group. AFP,CEA,CA125,CA19-9,CA15-3,FER and SCC were determined with automatic biochemical analyzer. Results Compared to desease group and benign group,CEA,CA125,CA19-9,CA15-3,FER,SCC of cervix cancer group were higher. Compared to desease group,CA125,CA15-3,FER and SCC were slightly higher in benign group. SCC was positively correlated with clinical staging,pathological grading,lymph node metastasis. The positive rate of joint detection on multi tumor markers was more than single metric in benign group and cervix cancer group,while cervix cancer group was higher than benign group. The differences were statistically significant（ P 0. 05）. Conclusion Joint detection on multi tumor markers can extremely increase diagnosis accuracy of cervix cancer.
作者
汪晓峰
魏仙风
唐春妍
WANG Xiao - feng WEI Xian - feng TANG Chun - yan(The Third People＇ s Hospital of Yuhang District, Hangzhou , Zhejiang 311115, China)
出处
《中国卫生检验杂志》
CAS
2017年第1期63-65,共3页
Chinese Journal of Health Laboratory Technology
关键词
宫颈癌
肿瘤标志物
联合检测
Cervix cancer
Tumor markers
Combined detection
